Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311188 | 0.95 | FFAR4 (0.39) | FFAR4TLR9TLR8TLR7PPARD | |
| SCHEMBL3267950 | 0.95 | FFAR4 (0.43) | FFAR4TLR9TLR8TLR7CCNT1 | |
| SCHEMBL1311879 | 0.95 | FFAR4 (0.43) | FFAR4TLR9TLR8TLR7CCNT1 | |
| SCHEMBL12113866 | 0.92 | FFAR4 (0.41) | FFAR4TLR9TLR8TLR7PPARD | |
| SCHEMBL12113788 | 0.92 | FFAR4 (0.46) | FFAR4TLR9TLR8TLR7PPARD | |
| SCHEMBL8932785 | 0.88 | FFAR4 (0.38) | FFAR4TLR9TLR8TLR7PPARD | |
| SCHEMBL1310804 | 0.88 | FFAR4 (0.39) | FFAR4TLR9TLR8TLR7PPARD | |
| SCHEMBL3272073 | 0.87 | FFAR4 (0.41) | FFAR4TLR9TLR8TLR7CCNT1 | |
| SCHEMBL1311476 | 0.87 | FFAR4 (0.41) | FFAR4TLR9TLR8TLR7CCNT1 | |
| SCHEMBL9562435 | 0.87 | RIPK1 (0.36) | FFAR4GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399896-B1 | LIQUID CRYSTALLINE COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE EACH COMPRISING SAME | JNC CORP (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8298632-B2 | Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition using this and liquid crystal display device | JNC CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2399896-A1 | LIQUID CRYSTALLINE COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT EACH COMPRISING SAME | JNC Corporation (JP) | 2011-12-28 | — | — | EP | disclosed |
| US-20110272630-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION USING THIS AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO PETROCHEMICAL CORPORATION (JP) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110272630-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION USING THIS AND LIQUID CRYSTAL DISPLAY DEVICE | PYM1, AQP1, CXCR1 | FFAR4 593/4885TLR9 3495/4885TLR8 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.